Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;463(1):17-22.
doi: 10.1007/s00428-013-1439-8. Epub 2013 Jun 21.

A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil

Affiliations

A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil

Juliana Giacomazzi et al. Virchows Arch. 2013 Jul.

Abstract

A few studies have reported phyllodes tumors (PT) of the breast with germline TP53 mutations. Given this potential association and the high frequency of the TP53 p.R337H in southern and southeastern Brazil, the aim of this study was to assess whether p.R337H occurs among women diagnosed with such rare tumors in this region. Benign, borderline, and malignant breast PT were retrieved from eight pathology laboratories, and DNA was extracted from tumor tissue to perform p.R337H analysis. Overall, 128 cases classified as benign, 7 as borderline, and 13 as malignant PT were included in the study. The TP53 p.R337H mutation was identified in tumor cells of eight (5.4 %) cases. Analysis of DNA from non-tumoral tissue was possible in two of these, and both were p.R337H carriers in the germline. In addition, haplotype analysis was done in these two p.R337H carriers showing the presence of the founder haplotype previously reported in Brazilian mutation-positive individuals. Mutation frequency was significantly higher among malignant (3 of 13; 23 %) compared to benign tumors (5 of 128; 3.4 %) (p = 0.004). Mean age at PT diagnosis was not significantly different between mutation carriers and non-carriers. However, when subgroups where analyzed, the difference in age at diagnosis of carriers versus non-carriers within the group of benign tumors reached borderline significance. Our findings reinforce previous evidence that TP53 mutations have an important role in the development of both benign and malignant PT of the breast.

PubMed Disclaimer

References

    1. PLoS One. 2011 Mar 22;6(3):e18015 - PubMed
    1. Cancer. 2011 May 15;117(10):2228-35 - PubMed
    1. Cancer. 1993 May 15;71(10):3020-4 - PubMed
    1. Am J Surg. 1993 Mar;165(3):376-9 - PubMed
    1. Cell Oncol. 2009;31(1):31-9 - PubMed

Publication types

LinkOut - more resources